Asher Holzer News Today

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Urogen Pharma (URGN – Research Report), with a p...

Goldman Sachs analyst Paul Choi maintained a Hold rating on Urogen Pharma (URGN – Research Report) on August 10 and set a price target of ...

ARK Investment Management LLC raised its position in UroGen Pharma Ltd. (NASDAQ:URGN – Get Rating) by 37.5% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 270,746 shares of the company’s stock after acquiring an additional 73,808 shares during […]

Globeflex Capital L P purchased a new stake in shares of UroGen Pharma Ltd. (NASDAQ:URGN – Get Rating) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 14,279 shares of the company’s stock, valued at approximately $127,000. Globeflex Capital L P […]

Opaleye Management Inc. boosted its position in UroGen Pharma Ltd. (NASDAQ:URGN – Get Rating) by 22.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 488,656 shares of the company’s stock after acquiring an additional 91,156 shares during the period. UroGen Pharma […]

Opaleye Management Inc. boosted its position in UroGen Pharma Ltd. (NASDAQ:URGN – Get Rating) by 22.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 488,656 shares of the company’s stock after acquiring an additional 91,156 shares during the period. UroGen Pharma […]

UroGen Pharma Ltd. (NASDAQ:URGN – Get Rating) was the recipient of a significant growth in short interest in April. As of April 15th, there was short interest totalling 743,700 shares, a growth of 16.3% from the March 31st total of 639,500 shares. Approximately 3.8% of the shares of the company are sold short. Based on […]

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Urogen Pharma (URGN – Research Report) today and set a price target of $2...

An Israeli startup is producing natural pharmaceutical-grade psychedelic extracts for a new generation of mental health therapeutics.

Markets Stifel Nicolaus analyst Derek Archila maintained a Buy rating on Urogen Pharma (URGN – Research Report) today. The company’s shares closed last Wednesday at $19.71. According to TipRanks.com, Archila is a 4-star analyst with an average return of 7.5% and a 43.1% success rate. Archila covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Madrigal Pharmaceuticals, and Phasebio Pharmaceuticals. The word on The Street in general, suggests a Strong B...